ALKS — Alkermes plc stock price and chart

Share this page

ALKS

$41.22+2.79%

as of close, Oct 16, 2026

☾ AH $41.22 +2.79%

Alkermes plcStock · HealthcareRussell 2000 0.3%Nasdaq Composite 0.02%US Stock Market 0.01%Russell 3000 0.01%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

15.020.025.030.035.040.045.050.055.060.0020.0M40.0M$41.22

2026-10-16

Price$41.22

MA20$45.67

MA50$36.71

Vol11.7M

What would $1,000 invested in ALKS be worth today? →

ALKS returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $41.22
YTD price return: +47.32%
YTD total return: +47.32%
Next earnings: Oct 27, 2026
Market cap: 6.9B2016-12 8.4B2026-10 6.9B-18.1% over the window
Enterprise value: 8B
Shares outstanding: 167.8M2016-06 151.6M2026-06 167.8M+10.7% over the window
52W low: $27.00
52W high: $55.67
From 52W high: -25.96%
From 52W low: +52.67%
52W range: 50%

Volume

Rel volume: 1.42×
30D volume: 2.3M
30D $ vol: 97.2M

Fundamentals

Sales (ttm): 1.7B2016-06 667.7M2026-06 1.7B+149.8% over the window
Sales/share: $9.942016-06 $4.412026-06 $9.94+125.6% over the window
EPS (ttm): $0.392020-06 -$0.792026-06 $0.39-149.1% over the window
FCF (ttm): 221.7M2016-06 -163.5M2026-06 221.7M-235.5% over the window
FCF/share: $1.322016-06 -$1.082026-06 $1.32-222.5% over the window
Book value/share: $10.782016-06 $8.212026-06 $10.78+31.4% over the window
Net margin: 3.97%2016-06 -41.2%2026-06 4.0%-109.6% over the window
ROE: 3.66%2016-06 -22.1%2026-06 3.7%-116.5% over the window
ROA: 1.51%2016-06 -15.4%2026-06 1.5%-109.8% over the window
Debt / equity: 0.82×2016-06 0.232026-06 0.82+258.6% over the window
Current ratio: 2.302016-06 3.932026-06 2.30-41.5% over the window

Growth (CAGR, ttm) · 10Y

Sales: +10.79%2025-06-30 → 2026-06-301.5B → 1.7B (+10.8% total)+4.48%2023-06-30 → 2026-06-301.5B → 1.7B (+14.1% total)+8.68%2021-06-30 → 2026-06-301.1B → 1.7B (+51.6% total)+9.59%2016-06-30 → 2026-06-30667.7M → 1.7B (+149.8% total)
Net income: -81.05%2025-06-30 → 2026-06-30348.4M → 66.1M (-81.0% total)-13.73%2023-06-30 → 2026-06-30103M → 66.1M (-35.8% total)n/an/a
FCF: -53.83%2025-06-30 → 2026-06-30479.8M → 221.7M (-53.8% total)+11.70%2023-06-30 → 2026-06-30159M → 221.7M (+39.4% total)+20.00%2021-06-30 → 2026-06-3089.1M → 221.7M (+148.9% total)n/a
Shares: +1.63%2025-06-30 → 2026-06-30165.1M → 167.8M (+1.6% total)+0.24%2023-06-30 → 2026-06-30166.6M → 167.8M (+0.7% total)+0.79%2021-06-30 → 2026-06-30161.3M → 167.8M (+4.0% total)+1.02%2016-06-30 → 2026-06-30151.6M → 167.8M (+10.7% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -81.25%2025-06-30 → 2026-06-30$2.08 → $0.39 (-81.2% total)-14.26%2023-06-30 → 2026-06-30$0.62 → $0.39 (-37.0% total)n/an/a
Sales/share: +9.02%2025-06-30 → 2026-06-30$9.12 → $9.94 (+9.0% total)+4.23%2023-06-30 → 2026-06-30$8.78 → $9.94 (+13.2% total)+7.83%2021-06-30 → 2026-06-30$6.82 → $9.94 (+45.8% total)+8.48%2016-06-30 → 2026-06-30$4.41 → $9.94 (+125.6% total)
FCF/share: -54.57%2025-06-30 → 2026-06-30$2.91 → $1.32 (-54.5% total)+11.44%2023-06-30 → 2026-06-30$0.95 → $1.32 (+38.4% total)+19.07%2021-06-30 → 2026-06-30$0.55 → $1.32 (+139.3% total)n/a
Book value/share: +9.55%2025-06-30 → 2026-06-30$9.84 → $10.78 (+9.5% total)+11.93%2023-06-30 → 2026-06-30$7.69 → $10.78 (+40.2% total)+9.64%2021-06-30 → 2026-06-30$6.81 → $10.78 (+58.4% total)+2.77%2016-06-30 → 2026-06-30$8.21 → $10.78 (+31.4% total)
Price: +33.86%2025-10-16 → 2026-10-16$30.80 → $41.22 (+33.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+13.71%2023-10-16 → 2026-10-16$28.03 → $41.22 (+47.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+5.41%2021-10-15 → 2026-10-16$31.67 → $41.22 (+30.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-0.26%2016-10-14 → 2026-10-16$42.30 → $41.22 (-2.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +33.86%2025-10-16 → 2026-10-16$30.80 → $41.22 (+33.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+13.71%2023-10-16 → 2026-10-16$28.03 → $41.22 (+47.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+5.41%2021-10-15 → 2026-10-16$31.67 → $41.22 (+30.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-0.26%2016-10-14 → 2026-10-16$42.30 → $41.22 (-2.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 105.6×2016-12 -32.912026-10 104.58-417.8% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 59.0×2016-12 -33.492026-10 58.97-276.1% over the window
Fwd P/E: 22.5×
P/S (ttm)Market cap ÷ TTM revenue.: 4.1×2016-12 12.152026-10 4.15-65.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.8×2016-12 6.982026-10 3.82-45.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 31.2×2016-12 -71.052026-10 31.20-143.9% over the window
EV/EBITDA (fy): 44.6×
EV/Sales (ttm): 4.8×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 3.21%2016-09 -1.4%2026-06 2.5%-279.1% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 167.8M ÷ 165.1M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -1.63%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-1.63%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($4.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -1.63%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($27.7M) ÷ today's market cap ($6.9B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.40%2016-09 0.0%2026-06 0.3%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $27.7M + TTM dividends $0) ÷ today's market cap ($6.9B). Same caveat as the cash buyback yield.: 0.40%2016-09 0.0%2026-06 0.3%

Vs own 10Y history

P/E: 92nd
P/OI: 78th
P/S: 65th
P/B: 54th
P/FCF: 44th

Bar = where today’s multiple sits in ALKS’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

+2.79%

+1.50%

-10.53%

-20.64%

YTD

+47.32%

+33.83%

+30.15%

Financial statements

Open full ALKS financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

ALKS — Alkermes plc price, chart and key statistics